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Abstract
The increasingly compelling data supporting the involvement of immunobiological mechanisms in Major Depressive
Disorder (MDD) might provide some explanation forthe variance in this heterogeneous condition. Peripheral blood
measures of cytokines and chemokines constitute the bulk of evidence, with consistent meta-analytic data implicating
raised proinflammatory cytokines such as IL6, IL1β and TNF. Among the potential mechanisms linking
immunobiological changes to affective neurobiology is the accelerated biological ageing seen in MDD, particularly via
the senescence associated secretory phenotype (SASP). However, the cellular source of immunobiological markers
remains unclear. Pre-clinical evidence suggests a role for peripheral blood mononuclear cells (PBMC), thus here we
aimed to explore the transcriptomic profile using RNA sequencing in PBMCs in a clinical sample of people with various
levels of depression and treatment response comparing it with that in healthy controls (HCs). There were three groups
with major depressive disorder (MDD): treatment-resistant (n= 94), treatment-responsive (n= 47) and untreated (n=
46). Healthy controls numbered 44. Using PBMCs gene expression analysis was conducted using RNAseq to a depth of
54.5 million reads. Differential gene expression analysis was performed using DESeq2. The data showed no robust
signal differentiating MDD and HCs. There was, however, significant evidence of elevated biological ageing in MDD vs
HC. Biological ageing was evident in these data as a transcriptional signature of 888 age-associated genes (adjusted
p < 0.05, absolute log2fold > 0.6) that also correlated strongly with chronological age (spearman correlation coefficient
of 0.72). Future work should expand clinical sample sizes and reduce clinical heterogeneity. Exploration of RNA-seq
signatures in other leukocyte populations and single cell RNA sequencing may help uncover more subtle differences.
However, currently the subtlety of any PBMC signature mitigates against its convincing use as a diagnostic or
predictive biomarker.
Introduction
Major Depressive Disorder (MDD) remains one of the
most aetiologically opaque of human disorders, yet one
that continues to exert a powerfully negative toll on
human health – physical as well as mental. MDD is both
heterogeneous in its phenotypic expression and complex
is its genetic and physiological correlates. Among the
latter there are increasingly compelling data supporting
the involvement of immunobiology in MDD. However,
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the mechanisms underpinning this relationship remain
unclear. Peripheral blood measures constitute the bulk of
evidence with consistent meta-analytic data implicating
raised proinflammatory cytokines. The most compre-
hensive genome-wide association study (GWAS) to date
on MDD used 7 major cohorts and identified 44 inde-
pendent loci and 153 genes1. Forty-five of these were in
the extended major histocompatibility complex (MHC),
which is central to acquired immunity and to leukocyte
interactions.
Whole-transcriptome studies offer another variant of
genome-wide search for disease-related mechanisms by
measuring mRNA expression levels of each gene in a
relevant tissue. RNA sequencing (RNA-seq) uses next-
generation sequencing to provide a quantitation of RNA
or gene expression. Recent studies have used this
method in MDD. One of the largest examined a total
sample of 922 people (463 with MDD and 459 health
controls) and sequenced RNA from whole blood2. A
relatively small number of genes were found to be
associated with MDD (29) at a very relaxed false dis-
covery rate (FDR) threshold of 0.25. With the more
customary and restrictive FDR threshold of 0.05, no
significant genes were found. They also showed modest
enrichment for the IFN α/β pathway, which included
three significant genes at FDR < 0.25.
A number of potential mechanisms have linked
immunobiological changes to affective neurobiology.
Among these is the accelerated biological ageing seen in
MDD. Immune cell senescence has a well-documented
effect on both epigenome and transcriptome3. MDD has
also been linked to the senescence associated secretory
phenotype (SASP), a dynamic secretory molecular path-
way indicative of cellular senescence4. This speaks to a
more elaborate biology linking cell biology, transcriptome
and inflammatory proteins produced by the cell.
The cellular source of immunobiological markers in
depression remains a key unanswered question. PBMCs
are a key source of peripheral cytokines and pre-clinical
models have suggested some PBMC subsets can enter the
brain and contribute to onset of sickness behaviour in
the context of stress. Monocytes recruited to the brain
have been linked to behavioural changes associated with
anxiety and with direct effects on neuronal dendritic spine
remodelling linked to cognitive deficits5–7. Similarly,
CD4+T cells have been to linked to stress-related
behavioural changes via mitochondrial fission leading to
xanthine upregulation and subsequent oligodendrocyte
proliferation in the amygdala8.
Given the weight of the preclinical evidence suggesting
a role for PBMCs, we aimed to explore the transcriptomic
profile using RNA-seq in PBMCs in a clinical sample of
people with various levels of depression and treatment
response and compare with that in healthy controls.
We aimed to answer the following research questions.
(1) Is there evidence of differential gene expression
between healthy controls and MDD or between
healthy controls and sub-types of MDD?
(2) Is there evidence of elevated immune ageing MDD
compared to healthy controls?
Methods
Participants
This was a non-interventional study, conducted as part
of the Wellcome Trust Consortium for Neuroimmunol-
ogy of Mood Disorders and Alzheimer’s disease (NIMA).
There were five clinical study centres in the UK: Brighton,
Cambridge, Glasgow, King’s College London, and Oxford.
All procedures were approved by an independent
Research Ethics Committee (National Research Ethics
Service East of England, Cambridge Central, UK; approval
number 15/EE/0092) and the study was conducted
according to the Declaration of Helsinki. All participants
provided informed consent in writing and received £100
compensation for taking part.
Sample and eligibility criteria
We recruited four groups of participants: treatment-
resistant depression, treatment-responsive depression,
untreated depression, and healthy volunteers.
Eligibility criteria can be viewed in full in Supplemen-
tary Information (Supplementary Table 1).
Patients were assigned to one of three subgroups or
strata, per protocol:
(i) treatment-resistant (DEP+MED+) patients who
had total Hamilton Depression Rating Scale
(HAM-D) score > 13 and had been medicated
with a monoaminergic drug at a therapeutic dose
for at least 6 weeks;
(ii) treatment-responsive (DEP-MED+) patients who
had total HAM-D < 7 and had been medicated
with a monoaminergic drug at a therapeutic dose
for at least 6 weeks; and
(iii) untreated (DEP+MED−) patients who had HAM-
D > 17 and had not been medicated with an
antidepressant drug for at least six weeks.
Questionnaire assessments
Psychological symptoms and childhood adversity were
assessed by administration of questionnaires as previously
described9 (see Supplementary Information). Baseline
depression severity was rated using the 17-item HAM-D.
Sampling and isolation of PBMCs
Whole blood was collected in K2EDTA tubes (BD,
USA) by peripheral venepuncture and allowed to cool to
room temperature for a minimum of 45 min. PBMCs were
collected from the interphase following density gradient
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centrifugation. RNA was extracted using the RNeasyMini
Kit (Qiagen, Germany) as per the manufacturer’s
instructions. RNA was eluted in 50 μl RNase-free H2O
and stored at −80 °C before being sent for sequencing.
RNA-sequencing and processing
PBMC samples were taken from four separate popu-
lation groups as follows: 44 healthy controls, 94 MDD
treatment-resistant, 47 MDD treatment-responsive and
46 MDD untreated patients. All PBMC samples had an
RNA Integrity Number (RIN) ≥ 8 and were analysed for
gene expression levels by RNA-Seq to an average depth
of 54.5 million read pairs. Reads were trimmed using
Cutadapt 1 (version cutadapt-1.9.dev2)10. The reference
used for mapping was the Homo sapiens genome from
Ensembl, assembly GRCh38, annotation version 84.
Reads were aligned to the reference genome using
STAR 2 (version 2.5.2b)11. Reads were assigned to fea-
tures of type ‘exon’ in the input annotation grouped by
gene_id in the reference genome using featureCounts 3
(version 1.5.1). Strandedness was set to ‘reverse’ and a
minimum alignment quality of 10 was specified. After
filtering for only protein coding genes, we observed a
median of 40 million exonic aligned reads per sample
(>85%).
RNA-sequencing differential expression analysis
Differential expression analysis was performed using
DESeq2 (version 1.18.1)12. The count matrix was initi-
ally filtered to include only coding genes, with a mean of
>1 read per sample. For the comparisons of binary
clinical covariates (e.g. gender, tobacco) one group was
compared to the other. For continuous clinical covari-
ates (e.g. age, BMI) the patients in the lower quartile
were compared to those in the upper quartile. No
additional covariates were used in the DEseq2 model
when comparing clinical covariates. For the compar-
isons between HC group and the MDD groups the 15
clinical covariates (Fig. 1b) identified as having >5 sig-
nificant associated genes (adjusted p < 0.01) and “batch”
were included as covariates in the model. To control for
extreme outlier values typical in large and hetero-
geneous datasets, a Cooks cut-off of 0.2 was used. All
other parameters were left to default. Significance was
set at an adjusted p of <0.01. For full details see the
Supplementary Information.
Deconvolution analysis
The per sample distribution of cell types was estimated
by Cibersort13, using the Deseq2 normalised expression
values (no additional covariates) as the mixture file, and
the LM22 (22 immune cell types) signature gene file.
Quantile normalisation was disabled. All other parameters
were left to default.
RNA-sequencing randomised cases and controls
The 231 samples were randomised using the r function
“sample” (without replacement), and were then split into
two random groups, one with 44 samples and one with
187 samples (in line with the real group distribution
and n). These two groups were then differentially com-
pared using DESeq2 as described above. For full details
see the Supplementary Information (refs. 14,15).
Co-expression analysis
The co-expression network cluster analysis was based
on the analysis performed by Le et al.16 and used their
code as a template. The method is detailed in full in
Supplementary Information. Briefly, a correlation tree was
generated from the expression matrix based on Pearson
correlation coefficients and a topological overlap matrix.
Clusters were identified by cutting the tree at a height of
0.95. To identify any clusters with significantly different
gene expression between HC and MDD samples, a
metagene for each cluster was generated using per gene
Z-scores. For each cluster the mean expression z-score
across all genes in that cluster was calculated, for each
sample. The resultant scores for the HC samples were
compared to that of the MDD samples using an unpaired,
two-tailed T-test. p values were adjusted using the
Benjamini–Hochberg procedure.
Expression microarray analysis
The GSK-HiTDiP MDD17 microarray data was
downloaded from GEO (GSE98793) and the 22 samples
that were reported to have failed QC were removed. The
expression data was then quantile normalised using
Limma18. Unannotated probe sets were removed. To
control for genes represented by several different probe
sets, Jetset19 was used to select the probe set for each
gene with the highest Jetset score. This resulted in
20,191 valid probe sets. Differential expression analysis
was performed between the HC and MDD groups using
Limma, and included batch, age, gender and anxiety as
additional covariates. All other parameters were left to
default. The quantile normalised expression values were
corrected for batch using Limmas “removeBatchEffect”
function.
RNA-sequencing biological age meta-genes
A list of PBMC age associated genes was identified by
using Deseq2 to compare the samples of lowest to highest
quartile of age, as described above. Next the expression
values (non-corrected but outlier capped) for the PBMC
age related genes were scaled (per gene z-score), with the
sign inversed for genes that were downregulated with age.
Finally, the mean scaled value (across all sig genes) per
sample was calculated. This value was considered as the
samples biological age. The samples biological age was
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then plotted against the samples chronological age, and
the spearman correlation value determined. To optimise
this metric, we repeated over a range of adjusted p and
log2fold change cut-offs and selected the combination
with the greatest correlation with patient age. For full
details see the Supplementary Information.
Fig. 1 Quality control and identification of confounding variables. A Distribution of immune cell types across all 231 PBMC samples. Cell types
are shown on the x-axis, and the percentage of the cell population that is described by each cell type is shown on the y-axis. Each box represents all
231 samples. B Bar chart showing the number of significantly different genes (DESeq2 adjusted p value < 0.01) across all clinical parameters with at
least five significant genes. C Gene expression heatmaps highlighting the size and consistency of the confounding effects of age (left), gender
(middle), and BMI (right) on the PBMC RNA-seq data. Samples are given by column and differentially expressed genes (adjusted p < 0.01) by row.
Colour intensity indicated row scaled (z-score) gene expression, with blue as low and yellow as high. D Gene expression boxplots of the most
significantly different gene between youngest and oldest (ROBO1), male and female (ZFY), and lowest and highest BMI (CA1). Sample groups are
shown on the x-axis and gene expression values (Corrected DESeq2 normalised counts) on the y-axis.
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Results
Quality control and identification of confounding variables
The NIMA samples were deeply sequenced and aligned
to the human genome, exhibiting a high per sample
alignment and feature counts rate (>85% alignment,
median of 40 million exonic reads, per sample). Decon-
volution analysis13 showed the distributions of cell
types to be consistent between the samples and typical of
PBMCs (Fig. 1A). Deseq2 Differential expression analysis
identified fifteen potentially confounding clinical covari-
ates (each with >5 significant genes each at adjusted
p < 0.01) from a panel of 87 (Fig. 1B), with Age, Gender
and BMI showing the strongest effects by an order of
magnitude (1244, 625 and 203 significant genes respec-
tively). The expression profiles for the Age, Gender and
BMI associated genes were consistent across all samples
(Fig. 1C) and the most differential genes (Fig. 1D) were
consistent with the relevant biology (e.g. the most sig-
nificant gender related genes were UTX and HYA which
are X and Y linked20,21). We therefore concluded firstly
that the data was of a high quality both technically and
experimentally, and secondly that, given the size of the
observed effect in the primary data, it was appropriate to
control for the fifteen confounding clinical covariates in
the downstream analysis.
There is no robust evidence for a differential expression
signature between HC and MDD in PBMCs
We used differential expression analysis to characterise
any differences between HC and each of the MDD groups
(MDD, treatment-resistant, treatment-responsive and
untreated), using an adjusted p cut-off of <0.01, and
including all 15 confounding clinical covariates plus batch
as interaction terms. One significantly different gene was
evident between HC and MDD (HIST1H2AE, adjusted
p= 0.008) and none between HC and MDD responders,
MDD resistant or MDD untreated. We additionally tried
reduced differential models – without BMI, with Age, BMI
and Gender only and with Batch only, however it made no
meaningful difference to these results. Observing only one
significant gene suggested that either (1) the adjusted
p-value threshold was too strict, or (2) the adjusted p-value
threshold was reasonable, and we were observing type I
error at HIST1H2AE. When we viewed the per sample
expression at HIST1H2AE (Fig. 2A) it showed the differ-
ence in expression between HC and the MDD groups to
be highly subtle. This was also true for the two genes of
lowest p-value (non-significant) for each of the four
comparisons (Fig. 2A–D).
Fig. 2E highlights the two most significant genes from
each of two comparisons of randomised cases and con-
trols. Randomised groups are labelled G1–G4. At the 250
most highly significant genes for each comparison the
distributions of p-values were almost identical to that of
randomised cases and controls (Fig. 2F). This was in stark
contrast to age, gender and BMI. These observations
suggested that relaxing the adjusted p-threshold would
not increase the number of true positives. We next esti-
mated the number of false positives expected in this
dataset at a range of adjusted p thresholds by generating
50 differential expression comparisons using randomised
cases and controls and taking the median and maximum
numbers of significant genes (Fig. 2G). The results
showed that we would expect on average three false
positives at adjusted p < 0.01, suggesting that it was not
unlikely for HIST1H2AE to be false positive in this case.
Though it is difficult to prove a negative outright, the
balance of probabilities suggest that the data more
strongly supported the absence of a HC vs MDD differ-
ential expression signature in PBMCs.
There is no evidence for clusters of highly correlating
genes that are altered in MDD compared to HC
We next considered the possibility that a HC vs MDD
differential signature in PBMCs could be too subtle to
detect using single gene interactions. This could occur for
example if it originated from a subset of cells within the
population. Several transcriptomic studies have shown22–25
that subtle signatures can be reliably detected by collapsing
clusters of highly correlating genes into representative
metagenes for differential expression analysis. This acts to
reduce noise and multi-sample correction stringency at the
expense of single gene resolution. To do so we removed
genes with low expression (mean > 10, in the Combat
corrected data) or with exceptionally high coefficient of
variability (standard deviation/mean < 0.15), to reduce the
chance that correlations could be driven by technical
variability. Next, we generated a gene co-expression matrix
from the remaining 5356 genes and plotted it as a hier-
archically clustered heatmap (Fig. 3A). The heatmap
showed clear structure and confirmed the existence of
several clusters of highly correlating genes. To identify the
correlation clusters, we used the method as described in
Le et al.16 (Supplementary Information). We identified 48
gene clusters with at least 50 genes in each. To validate
these clusters, we plotted them as expression heatmaps
(Fig. 3B), which confirmed the highly correlating nature of
the genes in each. Next, we set out to determine whether
the expression at cluster metagenes differed between HC
and MDD. We generated per cluster metagenes and
compared the metagene expression for HC samples to
MDD samples. We observed no significant difference (p <
0.25, unpaired, two tailed t-test with Benjamini–Hochberg
correction) between HC and MDD in any cluster (data not
shown). Boxplots of the six clusters of lowest p-value (non-
significant) highlighted the absence of any convincing
biological differences at each cluster (Fig. 3C). We there-
fore concluded that there was no evidence for clusters of
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Fig. 2 There is no evidence for a classical differential expression signature between HC and MDD in PBMCs. A Gene expression boxplots
highlighting the most significantly different genes between HC and MDD. Sample groups are shown on the x-axis and gene expression values (DESeq2
normalised counts) on the y-axis. B As A however for HC vs the MDD treatment-resistant group. C As A however for HC vs the MDD treatment-responsive
group. D As A however for HC vs the MDD untreated group. E As A however for the two most significant genes from each of two comparisons of
randomised cases and controls. Randomised groups are labelled G1–G4. F Distribution of differential expression p-values highlighting the consistency
between HC vs MDD and randomised cases and controls. The 250 most significant genes for each comparison are shown on the x-axis (ranked from
lowest to highest) and the p value (as−log10) on the y-axis. Lines are given for the three confounding variables Gender (‘male vs female’), Age (‘youngest
vs oldest’), BMI (‘lowest vs highest’), HC vs the four MDD types (MDD, MDD treatment-resistant, MDD treatment-responsive and MDD untreated) and for
the average of 50 comparisons of randomised cases and controls (‘random’). G Bar charts highlighting the number of differentially expressed genes that
were expected to be false positives by adjusted p threshold, based on 50 iterations of randomised cases and controls. The adjusted p threshold is given
on the x-axis and the median (left) and maximum (right) number of expected false positives on the y-axis.
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highly correlating genes that are altered in MDD compared
to HC in this dataset.
False positive genes were not random in PBMC data
We observed in our 50 differential comparisons invol-
ving randomised cases and controls that the most sig-
nificant genes included genes of immune function (such
as TNF and IFIT2) more frequently than we expected.
This raised the possibility that false positives genes might
preferentially be immune genes when looking at PBMCs.
To test this hypothesis, for each gene we took the mean
p-value across the fifty randomised comparisons, then
selected the 50 most highly significant genes by mean
p-value. We ran over representation analysis on the genes
(using DAVID with GO biological processes and a back-
ground of the PBMC expressed coding genes) and found
nine significantly enriched (<5% FDR) gene ontologies
(Supplementary Table 2). All were immune related
with the top three being “response to virus”, “type I
interferon signaling pathway” and “cellular response to
Fig. 3 There is no evidence for clusters of highly correlating genes that are altered in MDD compared to HC. A Gene co-expression heatmap
highlighting the presence of clusters of highly correlating genes in PBMC data. The x and y-axis show the 5356 highly correlating genes. The colour
intensity indicates the spearman correlation value between two given genes with blue as low and yellow as high. To highlight the presence of co-
expression clusters the heatmap has been hierarchically clustered on both axes using Spearman distances, with UPMGA agglomeration and mean
reordering. B Gene expression heatmaps for six gene co-expression clusters, highlighting the consistency between the expression pattern of all genes
within a cluster across all 231 samples. Samples are given by column and cluster genes by row. Colour intensity indicated row scaled (z-score) gene
expression, with blue as low and yellow as high. C Gene expression boxplots for the six clusters with the lowest p-value (T-test) for HC vs MDD. Showing
sample group on the x-axis and the cluster metagene expression (mean z-score) on the y-axis. All clusters are non-significant with adjusted p > 0.25.
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interleukin-1” and included the genes IFIT1, IFIT2, IFIT3
and CCL8. As we used a background specific to PBMCs,
this enrichment was relative to PBMCs and not other cell
types. Thus, was suggestive that genes of these immune
functions are more prone than other classes of genes to
the type of stochastic noise that can result in a false
positive. Therefore, indicating that false positives are not
random in these data and show a significant bias towards
certain immune functions. This further supported that it
would not be reasonable to relax the adjusted p threshold
when comparing HC to MDD, as it would likely introduce
an erroneous immune signal that could be confused for
bona-fide.
Relative to patient age biological age is significantly
greater in MDD patients than HC
To explore whether MDD patients showed increased
biological ageing compared to HC, we estimated the
biological age of each sample by taking the mean
expression value (z-score) across all the age-related
genes (see Methods section and Supplementary Meth-
ods for full details) and plotted it against chronological
age (Fig. 4A). As expected, we observed a strong positive
and significant linear correlation between biological and
chronological age (Spearman Correlation Coefficient
(SCC)= 0.72, p < 0.01). To determine whether MDD or
HC patients showed altered biological ageing (relative
to chronological age) we performed a linear regression
using the model biological age ~ chronological age
(Fig. 4A). Next, we counted the number of HC or MDD
patients above or below the regression line and found a
subtle (HC – 26 below (59%), 18 above (41%), MDD –
78 below (42%), 109 above (58%)) but significant dif-
ference (p < 0.05, Fisher’s exact test). To illustrate the
difference in distribution, we used the residuals – i.e.
the distance along the y-axis of each dot from the
regression line (Fig. 4B). Finally, to validate the result we
replicated the analysis using the GSK-HiTDiP MDD
whole blood microarray data. The results were com-
parable to PBMCs (Fig. 4A, B), with the MDD patients
showing significantly elevated biological ageing relative
to chronological ageing (HC – 35 below (61%), 22 above
(39%), MDD – 48 below (42%), 65 above (58%)),
p < 0.05, Fisher’s exact test).
Discussion
In this large, well-controlled and deeply sequenced
data-set, we find no evidence for a differential expression
signature in PBMCs between HC and MDD – as a whole
or in the subtypes described; nor is there evidence for
clusters of highly correlating genes that are altered in
MDD compared to HC. We also found that biological age
relative to chronological age is significantly greater in
MDD patients than in HC.
Our differential analysis showed only one gene to differ
significantly (adjusted p < 0.01) between HC and MDD
and none between HC and MDD sub-groups. Further
investigation concluded that, given the concurrence
between the distribution of p values for random samples
and the HC and MDD group comparisons, the very low
difference in expression between HC and MDD groups at
these genes, and the numbers of expected false positives at
this adjusted p-threshold, this was most likely a false
positive, unlikely to be biologically meaningful, and that
there was no justification for relaxing the p value
threshold in this data. To test whether any HC vs MDD
signature might be too subtle to detect at the single gene
level, we generated 48 gene co-expression clusters and
compared the metagenes between HC and MDD. We
observed no significant differences in any cluster, or any
convincing biological differences. We therefore concluded
that the data more strongly supported the absence of a
HC vs MDD differential expression signature in PBMCs.
In addition, when we randomised cases and controls 50
times and performed over representation analysis, we
found the most significant false positives to not be ran-
dom but to have a significant immune phenotype,
including “response to virus” and “type I interferon sig-
nalling pathway”. This further justified not relaxing the
adjusted p threshold in this data, as doing so would likely
introduce an erroneous immune signature that could be
interpreted as bona fide.
These results are, in many ways, comparable to previous
transcriptomic studies in whole blood which also found
no signature at adjusted p < 0.05 using larger sample
numbers2. One strength of our approach is that we con-
trol for age, gender and BMI in our sample selection. In
our opinion, we could not justify relaxing our adjusted
p threshold. However, other studies identified signatures
at adjusted p values ranging from p < 0.1 to p < 0.25.
A further strength of our study is that we present the per
sample expression values for all genes of interest. We would
argue that as other data2,26 presented signatures that were
detectable only at adjusted p > 0.05 using ~1000 samples
each, these signatures are likely to be subtle. However, the
omission of per sample expression data at the genes of
interest, makes it difficult to establish how subtle and so it is
difficult to form a robust opinion of how biologically
meaningful these expression differences are.
As mentioned in the introduction, evidence for an
inflammatory protein signature in MDD is substantial. This
is particularly the case for the proinflammatory cytokine
IL-6, with several meta-analyses confirming this. There is
also a longitudinal association between MDD and IL-627,
yet the tissue source of cytokines remains unclear. Our data
strongly suggest that in this sample of MDD, the source of
cytokines is unlikely to be PBMCs. Reflecting on other
potential sources; neutrophils are increasingly seen as
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important for fine regulation of the immune-inflammatory
response, outnumbering PBMCs by one or two orders of
magnitude28. Neutrophils produce a large variety of che-
mokines and cytokines upon stimulation and can differen-
tially switch phenotypes, displaying distinct subpopulations
in different microenvironments29. If neutrophils confer the
cytokine signature, it would be expected that gene expres-
sion studies of whole blood would capture their contribu-
tion. Another potential cell source are endothelial cells.
These are ubiquitous in both brain and periphery. Recently,
Blank et al. demonstrated a specific role in relation to
aspects of depression-relevant behaviour in mice by show-
ing that downstream signalling of brain endothelial cells
induces fatigue and cognitive impairment via impaired
neurotransmission in the hippocampus30. However, asses-
sing the individual contribution of endothelial cells in
humans would be technically very challenging. Never-
theless, considering findings presented in a recent GWAS of
MDD, it is important to consider that peripheral tissues
may have less of an overall contribution than the brain.
Wray et al. integrated their GWAS data with functional
genomic data, comparing their findings with bulk tissue
RNAseq from genotype tissue expression (GTEx)1. Here
only brain tissue showed enrichment, with the areas
showing the most significant enrichment being cortical.
This was in contradistinction to other tissue types including
whole blood.
The issue of body mass in MDD is complex. Wray et al.
found significant positive genetic correlations with body
mass1 and Mendelian randomization (MR) analysis was
consistent with BMI being causal or correlated with causal
risk factors for depression. Also, negative MR results
Fig. 4 Relative to patient age biological age is greater in MDD patients than in HC. A Scatterplots for PBMC RNA-seq data (left) and whole
blood expression microarray data (right), showing the correlation between chronological age (x-axis) and biological age (y-axis) as defined by the
mean expression z-score across all age-related genes, per sample. A linear regression line, alongside the Spearman Correlation Coefficient (SCC) and
associated p-value is shown. B Density plots of the residuals from the linear regressions in A. A positive residual indicates a sample above the
regression line and negative below.
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provide important evidence of no direct causal relationship
between MDD and subsequent changes in BMI. Adipose
tissue actively secretes cytokines and obesity is itself asso-
ciated with changes in the secretome of adipocytes leading
to increased production of proinflammatory cytokines31.
This raises the possibility that adipocytesmay be a potential
source of inflammatory cytokines acting as a tissue
“reservoir”. Careful consideration should be applied when
deciding whether BMI should be treated as a confounding
variable in MDD or incorporated as part of disease
pathogenesis.
We demonstrated that MDD samples showed sig-
nificantly elevated biological age compared to HC.
Although significant, the effect was relatively subtle,
comparable to that identified in CpG methylation data32.
Diniz et al. found MDD exhibited greater molecular
senescence in young and middle-aged adults by examin-
ing the impact of MDD on the senescence associated
secretory phenotype (SASP), a dynamic secretory mole-
cular pathway indicative of cellular senescence4. More
severe episodes of depression present with higher SASP
indices and a significant interaction between current
MDD episode and overweight, thus comorbid current
MDD plus being overweight had the highest SASP index.
While we have not correlated with direct measures of
senescence such as SASP indices or epigenetic markers,
we would argue that our finding is consistent with the
literature and points to a potentially interesting biology.
The strengths of this study lie in the high-quality RNA
and large clinical dataset, sequenced to an average depth
of >54.5 million reads, which aligned with >70% of the
reads mapping to exons. Thus, a deeply sequenced, well-
controlled clinical sample. The limitations of this study
relate to heterogeneity inherent in MDD. Within our
study, there was also some heterogeneity within the
assessing of prior medications as this was done using
retrospective self-reporting, albeit based on a compre-
hensive structured instrument completed by an inter-
viewer. The lack of medical comorbidities was an a priori
decision and can be seen as both a strength in removing
the potential confound of comorbid inflammatory illness
and a limitation in respect of the typicality of an
MDD group.
The age range is relatively narrow and could be seen as
a limitation in relation to interpretation of biological
ageing. Lastly, we did not measure cytomeglaovirus
(CMV) serostatus, which has been associated with dif-
ferences in immune cell profiles33.
Conclusion
This study was a detailed and careful examination of
the transcriptomic signal in PBMCs in MDD and HCs.
The lack of a significant differentiating signal between
MDD and HCs was confirmed by the randomisation of
the cases and controls. There was, however, evidence of
elevated biological ageing relative to patient age in MDD
vs HC. Future work should endeavour to expand clinical
sample sizes, reduce MDD heterogeneity and account for
confounds from the outset. Advances in RNA-seq at the
level of the single cell may help uncover further, more
subtle differences. However, the subtlety of any signature
mitigates against convincing use as a diagnostic or pre-
dictive biomarker, and tissue enriched data is strongly
indicative of brain tissue being the most informative in
this regard.
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